Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

doi:10.5306/wjco.v12.i4.249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4212)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

196

WORD

216

HTML

1781

Figures (1-1)

250

Tables (1-7)

317

Sum=2760

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

407

Download

1045

Sum=1452

Apr 24, 2021 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Apr 24, 2021; 12(4): 249-261
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249

Table 5 Sites of recurrence

	PET-CMR, n = 5	Non-PET-CMR, n = 17	P value
Local	0	4	0.66
Distant	5	16
Extraregional LN	3	6
Liver	0	5
Bone	1	4
Lung	1	3
Pleura	0	2

LN: Lymph node; PET-CMR: Positron emission tomography-complete metabolic response.

Citation: Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.249